Heather Bresch, Mylan CEO (Pablo Martinez Monsivais, AP Images)
June 19, 2020 06:42 AM EDT
Pharma
FDA+

Hours af­ter block­buster patent win, My­lan asks the FDA to speed up an OK to mar­ket a gener­ic to Bio­gen’s Tec­fidera

John Carroll

Editor & Founder

Hours af­ter Bio­gen was hand­ed a key de­feat in fed­er­al court, los­ing patent pro­tec­tion that would have pro­tect­ed the multi­bil­lion-dol­lar fran­chise drug Tec­fidera to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times